Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Corazon USA LLC

Neither a doctor nor a teaching hospital

Research payments

$1,839,609

206 payments

Through program year 2025, Corazon USA LLC is reported as receiving $1,839,609 in research payments, across 206 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $715,698 81
2024 Research $692,574 72
2023 Research $154,207 20
2022 Research $73,161 13
2021 Research $148,871 18
2020 Research $55,098 2

Breakdown

Who paid Research payments · program years 2020–2025
  1. AbbVie, Inc. $942,738 113 payments
  2. Eli Lilly and Company $451,210 19 payments
  3. Amgen Inc. $119,923 3 payments
  4. GlaxoSmithKline, LLC. $90,272 22 payments
  5. Horizon Therapeutics plc $44,070 2 payments
  6. Aurinia Pharma U.S., Inc. $38,640 9 payments
  7. Sun Pharmaceutical Industries Inc. $34,331 12 payments
  8. Novartis Pharmaceuticals Corporation $32,450 3 payments
  9. Argenx US, Inc. $29,999 13 payments
  10. Regeneron Pharmaceuticals, Inc. $26,726 5 payments
Studies the money was for Research payments · program years 2020–2025
  1. Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) $257,945 20 payments
  2. Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) $173,784 22 payments
  3. Efficacy and Safety of Ixekizumab Or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Active Psoriatic Arthritis and Obesity Or Overweight: A Phase 3B, Randomized, Multicenter, Open-Label Study (Together-Psa) $129,872 3 payments
  4. A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) $111,107 17 payments
  5. A Randomized, Controlled Pragmatic Phase 3B/4 Study of Baricitinib in Patients With Rheumatoid Arthritis $97,037 5 payments
  6. A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) $90,421 11 payments
  7. P4 Uncontrolled Gout FORWARD II $83,023 1 payment
  8. A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) $82,491 12 payments
  9. Efficacy and Safety of Ixekizumab Or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-To-Severe Plaque Psoriasis and Obesity Or Overweight: A Phase 3B, Randomized, Multicenter, Open-Label Study (Together-Pso) $63,871 3 payments
  10. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus $59,997 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record